First Mature Estimation of Median OS for Selpercatinib in Patients with RET Fusion-Positive NSCLC By Ogkologos - March 12, 2025 735 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from final efficacy and safety analyses from the LIBRETTO-001 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Advocates for Equal Access to Optimal Cancer Care for all Patients with Cancer at the 79th World Health Assembly Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic Ductal Adenocarcinoma FDA Approves Vepdegestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast Cancer MOST POPULAR High-Fat Diet or Diabetes Drug May Enhance Response to Targeted Cancer... August 8, 2018 Η ΚΑΘΗΜΕΡΙΝΟΤΗΤΑ December 10, 2018 Could a Vaccine Prevent Colorectal Cancer in People with Lynch Syndrome? April 19, 2019 Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab Prolongs OS Among... November 8, 2024 Load more HOT NEWS Utility of Serial ctDNA in Guiding Anti-EGFR Rechallenge in Metastatic Colorectal... 11-Year-Old Cancer Survivor With One Leg Dances With Professional Tapper Lord... Patients with Breast, Colorectal, and Pancreatic Cancers With ATM, CHEK2, or... Tisagenlecleucel Is Safe and Effective in Pretreated Patients with Relapsed/Refractory Follicular...
